Kanagawa, Japan, 29 May 2019 – FIMECS, Inc. (“FIMECS”), a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Yusuke Tominari, Ph.D., Chief Executive Officer and Chief Scientific Officer of FIMECS, will make a presentation at 20th Annual Drug Discovery Summit (11-12 June, 2019 in Berlin, Germany). Title is
“Case Study of Targeted Protein Degradation For Immune-Oncology Program, IRAK-M Degrader” and we will present the progress of our IRAK-M degrader program.
For more information:
https://www.oxfordglobal.co.uk/drugdiscovery-summit1/
About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDSTM platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects.
# # #
FIMECS, Inc. Media and Investor Contact:
Yusuke Kohno, CFO and VP of Corporate Development
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
TEL: +81-50-5328-9458
E-mail: info@fimecs.com